<DOC>
	<DOCNO>NCT02879383</DOCNO>
	<brief_summary>The Revita System intend improve glycemic control patient Type 2 diabetes preserve pancreatic beta cell function whose diabetes poorly control oral anti-diabetic medication . The purpose study demonstrate efficacy safety Fractyl DMR Procedure use Revita System compare sham procedure treatment uncontrolled type 2 diabetes . Subjects randomize DMR procedure follow per protocol 48 Weeks . The Sham treatment arm cross receive DMR treatment 24 week background medication hold constant 24-48 week follow .</brief_summary>
	<brief_title>Effect DMR Using Revita System Treatment Type 2 Diabetes ( T2D )</brief_title>
	<detailed_description>The study multi-center , randomize , prospective , double-blinded ( subject endocrinologist ) trial type 2 diabetes patient sub-optimally control 2 oral anti-diabetic medication compare Fractyl DMR procedure sham procedure . Subjects meet criterion screen randomize 1:1 ( DMR sham ) , double blinding ( subject endocrinologist ) . The endoscopist blind . All subject participate 4 week oral anti-diabetic medication run-in period index procedure confirm lack blood glucose control conjunction medication compliance nutritional counseling also allow withdrawal hypoglycemic anti-diabetic medication ( i.e . sulfonylurea meglitinide class ) . Subjects randomize DMR procedure follow per protocol 48 Weeks . Subjects randomize sham procedure follow 24 week offer cross DMR procedure . Cross-over subject follow per protocol additional 48 Weeks . The Sham treatment arm cross receive DMR treatment 24 week background medication hold constant 24-48 week follow . The DMR treatment arm follow intensify treatment algorithm 24-48 week follow allow addition oral anti-diabetic medication ( absent hypoglycemic agent ) GLP1 insulin need attain target HbA1c level 7.0 % . Mechanism action assessment include : ambulatory blood pressure monitoring , Mixed Meal Tolerance Test ( MMTT ) , Urine Micro Albumin , Radiological Hepatic Status . Subject follow visit occur 7 14 day ( phone ) 4 , 12 , 18 , 24 , 36 48 week ( clinic ) post procedure .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . 2875 year age 2 . Diagnosed Type 2 Diabetes evidence preserve insulin secretion . Fasting insulin &gt; 10 μU/ mL . 3 . HbA1c 7.5 10.0 % ( 5986 mmol/mol ) 4 . Body Mass Index ( BMI ) ≥ 24 ≤ 40 kg/m2 5 . On minimum 2 stable oral antidiabetic medication change medication previous 12 Weeks prior study entry 6 . Able comply study requirement understand sign inform consent 1 . Diagnosed Type 1 Diabetes history ketoacidosis 2 . Current use Insulin 3 . Current use GLP1 analogues 4 . Hypoglycemia unawareness history severe hypoglycemia ( 1 severe hypoglycemic event , define need thirdpartyassistance , last year ) 5 . Known autoimmune disease , evidence positive AntiGAD test , include Celiac disease , preexist symptom systemic lupus erythematosus , scleroderma autoimmune connective tissue disorder 6 . Active H. pylorus infection ( Participants active H. pylorus may continue screen process treat via medication retesting verifies condition resolve . ) 7 . Previous GI surgery could affect ability treat duodenum subject Bilroth 2 , RouxenY gastric bypass , similar procedure condition 8 . History chronic acute pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>28 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 2 Diabetes</keyword>
</DOC>